Juno Therapeutics Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Juno Therapeutics Reports First Quarter 2015 Financial Results
May 12, 2015 7:57 AM EDT
Leerink Partners Howard Liang reiterated an Outperform rating and $74 price target on Juno Therapeutics (NASDAQ: JUNO) following Q1 earnings and a deal to acquire Stage Cell Therapeutics GmbH. The deal, according to the analyst, keeps JUNO on the cutting edge of CAR Technology.
commented, "Along... More
May 11, 2015 4:09 PM EDT
Juno Therapeutics (NASDAQ: JUNO) reported Q1 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34).
Strong quarter-end cash position of$447.6 million.
Affirmed 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and now-settled litigation.
For earnings... More
May 11, 2015 4:08 PM EDT
Juno Therapeutics (NASDAQ: JUNO) acquired Stage Cell Therapeutics GmbH, a privately held biotechnology company based in Munich and Göttingen, Germany. The transaction furthers Juno's strategy of being a world leader in process development and the manufacturing of cellular therapies. The acquisition provides Juno access to transformative cell selection and activation capabilities, next generation manufacturing automation technologies, enhanced control of its supply chain, and lower expected long-term cost of goods. Juno plans to operate the acquired company,... More
